TGFB1 and Duchenne muscular dystrophy: Knowledge of the effect of the TGFβ pathway on the DMD phenotype provides a possibility of developing new treatments, and genotyping of the genetic variants involved could provide the clinician and the patient with more information on their possible progression or response to certain pharmacological treatments.